Am­i­cus stock jumps af­ter res­o­lu­tion of Galafold patent lit­i­ga­tion against Te­va

Am­i­cus Ther­a­peu­tics re­solved a patent dis­pute with Te­va on Thurs­day, al­low­ing Te­va to launch a gener­ic ver­sion of its Fab­ry dis­ease treat­ment Galafold in 2037 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER